Ergot is commonly supposed to produce a powerful and persistent contraction of blood vessels. This belief rests mainly on clinical evidence, which is not conclusive; even when the observations are correct, they generally admit of other explanations. For instance, the hemostatic action of ergot in postpartum hemorrhage is now referred to the contraction of the uterine muscle, rather than to a vasoconstriction.
It is also generally assumed that the vasoconstriction has been firmly established by experimental evidence. An inspection of any of the critical text-books of pharmacology, however, will suffice to show that different investigators have obtained variable results on mammals.
This caused us to undertake the present investigation, the original object of which was to determine, on dogs, the circulatory effects of the ergot preparations as found on the market, in therapeutic doses, normally and in the pathologic conditions in which the drug is recommended.
We intended to use
SOLLMANN T, BROWN ED. INTRAVENOUS INJECTION OF ERGOT.EFFECTS ON THE MAMMALIAN CIRCULATION. JAMA. 1905;XLV(4):229–240. doi:10.1001/jama.1905.52510040001001
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: